INTRODUCTION

Pulmonary hypertension (PH) is a progressive cardiovascular disorder of multiple etiologies that typically ends in death due to right heart failure (HF). Based on the World Health Organization (WHO) classification of PH, it is divided into 5 groups, of which PH due to left heart disease (PH- LHD) is the commonest. PH- LHD is described as a PH subtype with mean pulmonary artery pressure (mPAP) >25 mmHg and pulmonary artery wedge pressure (PAWP) >15 mmHg, although the threshold values of PAWP are controversial.

HF caused by LHD is mainly manifested as reduced ejection fraction (HFrEF), with preserved ejection fraction (HFrEF) and left-sided heart valve disease (VHD). The occurrence of PH in patients with LHD is a sign of disease progression. Nevertheless, therapeutic agents directly targeting patients with PH-LHD are not available. Although there have been some studies supporting the treatment of PH-LHD with targeted drugs for PAH, none has been applied to clinical treatment of PH-LHD. Effective treatments for LHD do not seem to improve PH-LHD, because PH-LHD is divided hemodynamically into pure postcapillary PH and combined pre- and...
postcapillary PH.\textsuperscript{18,19} The biggest difference lies in pure postcapillary PH simply being a bruise in the pulmonary veins, while the latter tends to occur with pulmonary artery vascular remodeling. Normally, they are difficult to distinguish from each other on the basis of clinical phenotype or symptoms. Some studies found that diastolic pulmonary vascular pressure gradients\textsuperscript{20–25} may be indicative of whether PH-LHD is accompanied by pulmonary vascular remodeling.

Hence, more in-depth studies are necessary to address the pathophysiology of PH-LHD and its pathogenic cellular and molecular signaling mechanisms, such as the increase in capillary pressure in the lungs caused by LHD affecting the dysregulation of endothelial homeostasis.\textsuperscript{26} Not much is known about the complex lesions and disease progression of PH-LHD, and an animal model that fully reproduces the pathological progression of human PH-LHD is still unavailable. Typically, PH-LHD animal models are mostly simulated models of PH due to HF. Moreover, the majority of patients with PH-LHD have metabolic syndrome manifestations,\textsuperscript{27} and recently there have been in vivo experiments to generate animal models of PH by simulating the metabolic syndrome of PH-LHD. Such studies will broaden our knowledge of PH-LHD with animal models that more closely approximate the disease, which will in turn lead to the development of better model options for preclinical treatments. The purpose of this review is to summarize the animal models of PH-LHD available at present and to outline the advantages and limitations of each model.

2 PH FROM PRESSURE OVERLOAD-INDUCED LEFT-VENTRICULAR (LV) FAILURE

LV failure can be induced by several pressure overload entities. The banding position for PH-LHD in animal models is summarized in Figure 1, which will be further discussed, and Table 1 lists the advantages and pitfalls of all PH-LHD animal models for various animal species. The left ventricle is highly sensitive to a rapid increment in afterload stress. In the majority of models, this causes a sudden rise in LV afterload that induces acute left HF, which may result in death in some animals. However, the phenotype of hemodynamics, including mPAP and/or right ventricular systolic pressure (RVSP), is different among various animal species. The main type commonly used at present is aortic banding or ascending aortic banding models.

2.1 Aortic banding (AoB)

AoB is a simple, ancient, and common surgical procedure in which a band is clamped around the aorta to increase afterload. In its early state, it was mainly used in studies focusing on cardiac dysfunction in hypertension,\textsuperscript{28} myocardia hypertrophy,\textsuperscript{29} or cardiac pressure-overload hypertrophy.\textsuperscript{30} In 2001, Backs et al. applied the AoB model to study congestive HF.\textsuperscript{31} The surgical procedure consisted mainly of ascending aortic binding in Wistar rats weighing about 90 g. The material used was a tantalum hemostatic clip (internal diameter 0.71 mm), and 4 weeks after surgery, it was evident that the left and right ventricular weight increased, and pulmonary stasis was noticeable compared with the sham group. Although RVSP and mPAP were not measured when the AoB rat model was first described, they could be predicted to be elevated based on the changes in right ventricular remodeling.

In principle, AoB mimics increased LV afterload, which passively causes an increase in LV ejection pressure and pressure conduction, leading to increased pulmonary venous pressure, eventually leading to chronic right HF and PH. In 2007, Hentschel et al. further modified an AoB animal model with a 0.8 mm diameter titanium clip, and hemodynamics were examined 9 weeks later. Compared with the sham group, the AoB rat model exhibited elevated mPAP, pulmonary vascular resistance (PVR), and left atrial pressure.\textsuperscript{32} In 2009, this research team used this rat model to study PH-LHD and found that inhaled nitric oxide improved pulmonary hemodynamics and pulmonary edema in group 2 PH.\textsuperscript{33} This animal model was further promoted, and aortic banding in rats is at present the most commonly used animal model to study PH-LHD,\textsuperscript{34–42} although the timing of the banding varies depending on the operator’s experience.

Due to its simplicity, feasibility, and high reproducitivity, AoB is commonly used in rat models to produce mild or medium PH-LHD.
depending on the aortic banding time according to the hemodynamics characteristics summarized in Table 1. Aortic banding is usually utilized in young rats. Given that the chance of death due to acute left HF after ligation might increase in older rats, the rats are generally required to be 80–100 g. As the rats grow, the banding becomes tighter, which causes severe LHD and PH.

| Method                          | Strengths                                                                 | Limitations                                                                 | Time                                      | RVSP/mPAP                                                                 | Species               |
|---------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------|---------------------------------------------------------------------------|-----------------------|
| Aortic banding (AoB)            | Simple; reprodicible; commonly used; simulates HFpEF; low cost            | Sudden initial afterload increased predisposition to left heart failure and death;    | 25 d, 6 wk, 7 wk, 9 wk, 4 months         | RVP (cmH2O) = 35, RVSP (mmHg) = 36, mPAP (mmHg) = 40                  | Rat, kitten          |
| Transverse aortic constriction (TAC) | Especially for mice; simulates HFpEF; low cost                           | Sudden initial afterload increased predisposition to left heart failure and death; infrequent; PH due to aortic stenosis is uncommon in human patients | 6 wk, 8 wk                           | RVSP (mmHg) = 35, = 40                | Mouse                |
| Descending aorta implanted by stent | Large animal; simulates HFpEF                                           | Operative difficulties; high cost; long time                                  | 5 months                                 | RVSP (mmHg) = 51                   | Swine                |
| Left atrial stenosis            | Less complicated; low cost; mimics PH-LHD caused by mitral valve lesions | Surgery bleeding; difficult to estimate LA pressure                            | 10 wk                                     | RVSP (mmHg) = 41                   | Rat                  |
| Pulmonary vein banding          | Large animal; simulation of congenital pulmonary vein stenosis; low mortality rate; reproducible | Complicated; high cost                                                       | 10 wk, 3 months                         | mPAP (mmHg) = 33               | Swine                |
| Ligation of left coronary artery| Mimics HFpEF-PH; low cost; simple                                        | Difficult to control the area of infarcts (size of pathological infarction only sufficient to develop HFpEF-PH) | 2 wk, 4 wk, 5 wk, 8 wk, 17 d | RVSP (mmHg) = 50                   | Rat, mouse, swine   |
| High-fat diets (HFD)            | Simple; mimics HFpEF-PH                                                  | Long time                                                                     | 20 wk, 16 wk                            | RVSP (mmHg) = 40               | Mouse                |
| Combined metabolic syndrome and pressure overload-induced PH-LHD | Mimics EFpHF-PH; closer to clinical patients with PH-LHD; double hit | Complicated phenotype; high cost                                              | 9 wk                                      | mPAP (mmHg) = 30                | Rat                  |
| Combined metabolic syndrome and SU5416-induced PH-LHD | Mimic EFpHF-PH; double hit; closer to clinical patients with PH-LHD | Complicated phenotype; high cost                                              | 14 wk                                    | RVSP (mmHg) = 40               | Rat                  |
In recent years, attempts to develop large animal models of left ventricular pressure afterload have been emerging. Gyöngyösi et al.43 implanted a bare metal stent (9 mm in diameter) into the descending aorta (immediately below the aortic arch) of pigs by left heart catheter insertion. At a 5-month follow-up, there was a significant increase in mPAP, RVSP, right ventricle mass, and LV hypertrophy as well as a trend toward decreased right heart function. Of note, this is a large animal model with a minimally invasive percutaneous method to slowly induce LV hypertrophy and secondary PH, which adds great translational value for novel target identification due to its simulation of human conditions.

2.2 | Transverse aortic constriction (TAC)

Another common model for pressure-load-induced HF in mice is TAC. In 1991, Rockman et al.44 first applied this model to the study of cardiomyocyte hypertrophy in mice by the ligation of transverse aorta using a 27 G blunt needle positioned between the innominate artery and the left carotid artery, which over a 6-week period established a mouse PH model caused by left HF with medium hemodynamic compromise (RVSP 35–40 mmHg).45,46 After TAC in mice, left ventricular insufficiency, right ventricular hypertrophy, increased RVSP, and elevated mPAP develop over time, accompanied by an increased degree of pulmonary fibrosis and infiltration of inflammatory cells.47 It has been demonstrated that the use of riociguat (a soluble guanylate cyclase agonist) or sildenafil (phosphodiesterase 5 inhibitor) improves pulmonary vascular remodeling and right heart function in TAC-induced PH-LHD.4 TAC in mice is not extremely challenging operationally and has a relatively high successful rate (80%–90%) with practice. In line with aortic banding, mice undergoing TAC also experience a sudden elevation in LV pressure, and acute left HF is more likely to occur if older mice undergo the procedure, so it is recommended to use younger mice, about 3–4 months of age.45

2.3 | Pulmonary vein banding (PVB)

To establish PVB model, the confluence of 2 main pulmonary veins is in principle nonrestrictively banded by surgery to narrow the pulmonary veins in experimental animals, causing obstruction of the pulmonary circulation flow and enhanced pulmonary venous afterload, followed by an increase in PAP and the eventual development of right HF. In 1972, Silove et al. applied a calf model of PVB to the study of progressive PH.48 In 1990, LaBourene et al. first used pulmonary vein ligation in piglets to study fibrosis of pulmonary veins.49 On this basis, in 2014, Pereda et al. first utilized this PVB surgery in a porcine model to simulate a part of the disease physiopathological process in PH-LHD.50 In the same year they described for the first time a swine model of pulmonary vein tying, they were the first to use large animals in the study of postcapillary PH as well as combined pre- and postcapillary or active PH.51

This model is generally applied to large animals, such as pigs. The observation period after surgery is usually 4 months, during which right heart catheterization is performed regularly, and it is the most common large animal model currently mimicking group 2 PH with medium hemodynamic compromise (mPAP 33–40 mmHg). The advantage of pulmonary vein narrowing is that it can simulate an animal model of PH caused by congenital pulmonary vein stenosis. The disadvantage lies in the high expense, and the procedure requires multiple operators.

2.4 | Left atrium stenosis (LAS)

In 2017, Yoshitaka et al. proposed the first LAS surgery in rat and successfully established a new PH-LHD rat model for the study of arterialization of the internal pulmonary veins.52 Those rats phenocopied medium PH-LHD as evidenced by an increase of RVSP to 41 mmHg. The model is operated by opening the chest and ligating left atrium using a larger clip under direct vision.53 One study found that LAS surgery simulated pulmonary venous arterialization and PH caused by the mitral stenosis. Echocardiographic findings post-modeling revealed a significant increase in mitral inflow velocity in rats receiving LAS surgery compared with those without, which is the first study to apply this model in PH caused by heart valve disease.54 It was also verified that increased left atrial area on computed tomography (CT) or magnetic resonance imaging (MRI) can predict the diagnosis of PH-LHD in patients.54,55 The LAS model is mainly applied in small animals of rats, which likewise adds a new option for the study of the molecular mechanisms of pulmonary venous arterialization.

3 | ISCHEMIC HEART FAILURE-INDUCED PH

Myocardial infarction models are the most widely used models in studies of cardiac ischemia, in which left anterior descending coronary artery was commonly ligated to induce myocardial infarction. This has been applied to the study of ventricular function since as early as the 1970s.56 However, the application of this model to the study of PH-LHD has drawn attention in recent years. In 1998, Quang et al.57 found that endothelin A receptor blockade did not abolish pulmonary fibrosis and vasculature remodeling in a rat model of myocardial infarction despite improvement in mPAP.58,59 The reason for coronary artery ligation inducing PH might be that it simulates HF caused by low cardiac output or low ejection fraction, which mimics the manifestation of PH. Normally, it takes approximately 5–8 weeks to develop PH for this model.

This model is commonly used in small animals such as rats or mice, but can also be applied to large animals such as swine. The left coronary circumflex artery can also be chosen for ligation, although it is less frequently selected compared with the left anterior descending coronary artery. This PH-LHD rodent models...
by ligation of left coronary artery displayed a medium to severe hemodynamic compromise with an increase of RVSP to the range of 40–52 mmHg, although swine exhibited only a mild PH phenotype developed by this method owing to a short observation period and species-specific physiology. The main disadvantage of left anterior descending ligation is the low postoperative survival rate, mainly due to surgery-induced cardiac arrhythmias in animals, bleeding, or death caused by pneumothorax. This model requires rigorous training and experience to ensure a high survival rate for animals undergoing the procedure. The strengths of a myocardial infarction-induced PH model are attributable to its recapitulation of HFpEF in humans, especially for patients with myocardial infarction resulting in myocardial cell necrosis, HF, and, finally, group 2 PH.

4 | METABOLIC MODELS OF PH-LHD

Metabolic syndrome is observed in the majority of patients with PH-LHD and includes hypertension, hyperlipidemia, and diabetes mellitus. Animal models of metabolic syndrome are new models that have been gradually developed in recent years compared with aforementioned PH models induced by HF.

4.1 | High-fat diets (HFD)

In 2016, Lai et al. first used a genetic rat model to study PH-LHD. They generated a double-hit rat model, combining metabolic syndrome as a consequence of obese ZSF1 with double-leptin receptor defect and pulmonary endothelial impairment by vascular endothelial growth factor receptor antagonist SU5416 for the first time, and found that RVSP was significantly increased to around 40 mmHg and the hemodynamic characteristics in rats were similar to the clinical features of human HFpEF-induced PH, indicating this model might be appropriate for the study of medium PH-LHD. It is currently the only genetic rat model that can be used in the study of PH-LHD with metabolic syndrome. Importantly, treprostinil together with metformin is able to improve HFpEF-induced PH, alongside ameliorating metabolic syndrome.

4.2 | Combined metabolic syndrome and pressure overload-induced PH-LHD

In 2019, Ranchoux et al. first described a complicated model of PH-LHD in rats together with AoB causing left ventricular diastolic dysfunction followed by HFD or intraperitoneal injection of olanzapine for 9 weeks. This model combines metabolic syndrome and left ventricular diastolic dysfunction for the first time, and the experimental rats exhibit increased PVR and pulmonary vascular remodeling, more closely simulating PH caused by HFpEF. Their study showed that metabolic syndrome significantly promotes diastolic dysfunction and remodeling of pulmonary vasculature in rats. Moreover, they confirmed that metformin not only improved the inflammatory environment of PH-LHD, but also mitigated pulmonary vascular remodeling in this PH-LHD model. However, the hemodynamic characteristics demonstrated a mild elevation of mPAP to approximately 30 mmHg at the end point, slightly higher than that of the AoB-only model, despite obvious lung vasculature remodeling as evidenced by a vascular wall thickness triple that in control rats. This would suggest this model might be appropriate for the study of mild PH-LHD rather than severe cases, and metformin may be a new promising therapeutic agent for those patients with mild PH-LHD accompanied by metabolic syndrome.

4.3 | Combined metabolic syndrome and SU5416-induced PH-LHD

In 2016, Lai et al. first used a genetic rat model to study PH-LHD. They generated a double-hit rat model, combining metabolic syndrome as a consequence of obese ZSF1 with double-leptin receptor defect and pulmonary endothelial impairment by vascular endothelial growth factor receptor antagonist SU5416 for the first time, and found that RVSP was significantly increased to around 40 mmHg and the hemodynamic characteristics in rats were similar to the clinical features of human HFpEF-induced PH, indicating this model might be appropriate for the study of medium PH-LHD. It is currently the only genetic rat model that can be used in the study of PH-LHD with metabolic syndrome. Importantly, treprostinil together with metformin is able to improve HFpEF-induced PH, alongside ameliorating metabolic syndrome.

5 | DIFFERENCES BETWEEN ANIMAL MODELS AND HUMAN PH-LHD

The distinctions between animal models and PH-LHD patients are not well studied. Some studies differ with regard to the timing of modeling in the AoB model, with one study reporting 25 days to produce right heart dysfunction, but most of the AoB models are established at 9 weeks post-bandng, which corresponds to the long time it takes for patients to develop PH-LHD and the right heart failure as a late response to left heart failure. PH-LHD patients with right heart failure sometimes manifest clinical signs of remission, when in fact the disease is further aggravated. The AoB model mainly recapitulates PH due to aortic stenosis. Nevertheless, its application to the study of other subtypes of PH-LHD (e.g., PH-LHD due to congenital cardiomyopathies) is challenging. For the mouse model of myocardial infarction-induced PH, the difference lies in the infarction area in the mouse model being relatively fixed, while there is no strict pattern of infarction region in patients with PH-LHD. Finally, in most patients, PH-LHD is accompanied by metabolic
syndrome, but it remains to be elucidated whether it is the metabolic syndrome affecting left or right heart function or LHD causing the metabolic syndrome. However, in the PH-LHD metabolic disorder model, a high-fat diet is usually applied to induce metabolic derangement, which might be inconsistent with the patients’ conditions.

6 | CONCLUSION AND PROSPECTS

Currently, therapies to improve or treat the long-term prognosis of PH-LHD are limited, with the diseased subpopulation occupying the largest proportion in PH. Despite the increasing understanding of the subgroup classification of PH-LHD and the continued development of animal models, many challenges remain in uncovering the pathophysiological mechanisms and in developing effective treatments for the disease because of the complexity of LHD, PH, and the metabolic disorders in PH-LHD. In preclinical studies of PH-LHD, none of the current available animal models, including aortic banding, left coronary artery ligation, and the recent combination of metabolic syndrome with aortic banding or vascular endothelial growth factor receptor blocker (Figure 2), can fully characterize PH-LHD and simulate the development of the disease. Although an attempt to apply an animal model of volume-loading-induced heart failure to the study of PH-LHD has been proposed, its incompatibility with the pathological process of the disease does not yet allow its mainstreaming. Considering PH-LHD caused by myxomatous mitral valve disease occurring in dogs, its predominant echocardiography findings do not support its establishment as a stable model. Although metabolomics has been employed in vivo models of PH challenged by monocrotaline, hypoxia, or SU5416/hypoxia at the tissue or cellular level or in vitro models (such as pulmonary arterial smooth muscle cells under the stimulus of hypoxia), to date, the metabolic reprogramming of animal models mimicking PH-LHD remains unveiled. Hence the application of metabolomics to the PH-LHD would provide critical information for our understanding of the metabolic mechanisms underlying PH-LHD, especially with metabolic perturbations.

Aside from the triggers of overload-induced LV failure, ischemic heart failure, or metabolic dysfunction, the genetic predisposition to PH-LHD at a large scale will require further investigation with the aid of next-generation sequencing, such as bone morphogenetic protein receptor 2 (BMPR2) as a pivotal predisposing gene for pulmonary arterial hypertension (PAH, group 1 PH). It is reported that BMPR2-deficient rats or Bmpr2+R899X knock-in mice display a spontaneous pulmonary vascular remodeling and have been widely applied to explore the pathogenesis of PAH. The generation of a new genetic rodent model might represent a promising tool to study the pathogenesis of PH-LHD and whether it has a synergistic effect with other factors (such as metabolic dysfunction). In fact, the role of epigenetic regulation (e.g., DNA methylation, histone acetylation, and noncoding RNAs) has been investigated in multiple PH animal models induced by either monocrotaline or hypoxia. However, its role in animal models of PH-LHD remains largely unknown. Furthermore, the study of specific gene profiling of PH-LHD in comparison with other PH subtypes or LHD would be of great benefit to the discovery of potential targets and, thus, the generation of PH-LHD induced by either monocrotaline or hypoxia. Given that sex hormones are associated with insulin resistance and metabolic syndrome, future studies on PH-LHD evaluating whether there exists a gender bias and investigating the detrimental or protective role of sex hormones are warranted. In addition, the differences in right ventricular adaptation/decompensation pattern of PH-LHD and other PH subtypes should be scrutinized as well, since LHD might affect the right ventricle much earlier.

A more stable and reproducible animal model is a requisite for the identification of novel and effective therapeutic approaches for PH-LHD treatment, and the development of an appropriate preclinical...
model of PH-LHD is urgently needed, which would allow us to better understand this disease and thus accelerate the development of new therapies.

ACKNOWLEDGMENTS
None.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS
S.-F. L. conceived and wrote the original draft manuscript and provided funding support. Y. Yan conceived and revised the manuscript.

ORCID
Shao-Fei Liu https://orcid.org/0000-0001-6178-5938
Yi Yan https://orcid.org/0000-0003-2860-3252

REFERENCES
1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34-D41. doi:10.1016/j.jacc.2013.10.029
2. Xu D, Zhang H, Cheng H, et al. Pulmonary hypertension due to left heart disease with pulmonary arterial wedge pressure ≤15mmHg. Herz. 2021;46:209-214. doi:10.1007/s00059-020-04983-3
3. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31:913-933. doi:10.1016/j.healun.2012.06.002
4. Dzudie A, Kengne AP, Thienemann F, Sliwa K. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. BMJ Open. 2014;4:e004843. doi:10.1136/bmjopen-2014-004843
5. Pradhan K, Sydzykov A, Tian X, et al. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. Int J Cardiol. 2016;216:85-91. doi:10.1016/j.ijcard.2016.04.098
6. Kido K, Coons JC. Efficacy and safety of the use of pulmonary arterial hypertension pharmacotherapy in patients with pulmonary hypertension secondary to left heart disease: a systematic review. Pharmacotherapy. 2019;39:929-945. doi:10.1002/phar.2314
7. Han B, Wang Q. Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease. Exp Ther Med. 2018;16:1175-1186. doi:10.3892/etm.2018.6310
8. Bermejo J, Yotti R, García-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39:1255-1264. doi:10.1093/eurheartj/ehy700
9. Jiang R, Wang L, Zhu CT, et al. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. Hypertens Res. 2015;38:829-839. doi:10.1038/hr.2015.73
10. Moghaddam N, Swiston JR, Tsang MYC, et al. Impact of targeted pulmonary arterial hypertension therapy in patients with combined post- and precapillary pulmonary hypertension. Am Heart J. 2021;235:74-81. doi:10.1016/j.ahj.2021.01.003
11. Vachiéry JL, Delcroix M, Al-Hití H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51:1701886. doi:10.1183/13993003.01886-2017
12. Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur J Heart Fail. 2015;36:2565-2573. doi:10.1093/eurheartj/ehv336
13. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502-511. doi:10.1161/CIRCULATIONAHA.113.001458
14. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension secondary to left ventricular dysfunc- tion: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502-511. doi:10.1161/CIRCULATIONAHA.113.001458
15. Simon MA, Vanderpool RR, Nouraie M, et al. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight. 2016;1:e89620. doi:10.1172/jci.insight.89620
16. Sun D, Yang W, Wang Z, Gao B. Efficacy of beraprost sodium combined with sildenafil and its effects on vascular endothelial func- tion and inflammation in patients experiencing left heart failure complicated with pulmonary arterial hypertension. Med Sci Monit. 2021;27:e928413. doi:10.12659/MSM.928413
17. Domingo E, Grignola JC, Trujillo P, Aguilar R, Roman A. Proximal pulmonary arterial wall disease in patients with persistent pul- monary hypertension after successful left-sided valve replacement according to the hemodynamic phenotype. Pulm Circ. 2019;9:2045894018816972. doi:10.1177/2045894018816972
18. Ibe T, Wada H, Sakakura K, et al. Combined pre- and post-capillary pulmonary hypertension: the clinical implications for patients with heart failure. PLoS One. 2021;16:e0247987. doi:10.1371/journal.pone.0247987
19. Gerges C, Gerges M, Fesler P, et al. In-depth haemodynamic phe- notyping of pulmonary hypertension due to left heart disease. Eur Respir J. 2018;51:1800067. doi:10.1183/13993003.0067-2018
20. Ibe T, Wada H, Sakakura K, et al. Pulmonary hypertension due to left heart disease: the prognostic implications of diastolic pul- monary vascular pressure gradient. J Cardiol. 2016;67:555-559. doi:10.1016/j.jcc.2015.07.015
21. Dragu R, Hardak E, Ohanyan A, Adir Y, Aronson D. Prognostic value and diagnostic properties of the diastolic pulmonary pres- sure gradient in patients with pulmonary hypertension and left heart disease. Int J Cardiol. 2019;290:138-143. doi:10.1016/j.ijcard.2019.05.016
22. Caravita S, Faini A, Carolino D’Araujo S, et al. Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: role of the pre-capillary component. PLoS One. 2018;13:e0199164. doi:10.1371/journal.pone.0199164
23. Nagy AI, Venkateshvaran A, Merkely B, Lund LH, Manouras A. Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hyper- tension due to left heart disease. Eur J Heart Fail. 2017;19:88-97. doi:10.1002/ejhf.675
24. Howard C, Rangajahavala K, Safdar Z. Pulmonary artery diastolic pressure gradient as an indicator of severity of illness in patients with pulmonary hypertension related to left-sided heart disease. Ther Adv Respir Dis. 2015;9:35-41. doi:10.1177/1753465815573373
25. Sugimoto K, Yoshihisa A, Nakazato K, et al. Significance of pulmo- nary vascular resistance and diastolic pressure gradient on the new definition of combined post-capillary pulmonary hypertension. Int Heart J. 2020;61:301-307. doi:10.1536/ihj.19-476

https://orcid.org/0000-0001-6178-5938

https://orcid.org/0000-0003-2860-3252
27. Ussavarungsi K, Thomas CS, Burger CD. Prevalence of metabolic syndrome in patients with pulmonary hypertension. Clin Respir J. 2017;11:721-726. doi:10.1186/crj.12406
28. Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation. 1993;87:1328-1339. doi:10.1161/01.cir.87.4.1328
29. Kromer EP, Riegger GA. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol. 1988;62:161-163. doi:10.1016/0002-9149(88)91389-6
30. Bruckschlegel G, Holmer SR, Jandeleit K, et al. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25:250-259. doi:10.1161/01.hyp.25.2.250
31. Backs J, Haunstetter A, Gerber SH, et al. The neuronal norepinephrine transporter in experimental heart failure: evidence for a post-transcriptional downregulation. J Mol Cell Cardiol. 2001;33:461-472. doi:10.1016/j.yjmcc.2000.1319
32. Hentschel T, Yin N, Riad A, et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology. 2007;106:124-131. doi:10.1095/200701000-00021
33. Yin N, Kaestle S, Yin J, et al. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med. 2009;37:980-986. doi:10.1097/CCM.0b013e3181962ce6
34. Huang W, Liu H, Pan Y, Yang H, Lin J, Zhang H. Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC/MAPK pathway and the expression of IL-6 and TNF-alpha. J Cardiothorac Surg. 2021;16:127. doi:10.1186/s13019-021-01471-5
35. Zhuang R, Wu J, Lin F, et al. Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of endstage pulmonary hypertension with left heart disease. Int J Mol Med. 2018;42:1341-1352. doi:10.3892/ijmm.2018.3728
36. Zhang H, Huang W, Liu H, Zheng Y, Liao L. Mechanical stretching of pulmonary vein stimulates matrix metalloproteinase-9 and transforming growth factor-beta1 through stretch-activated channel/MAPK pathways in pulmonary hypertension due to left heart disease model rats. PLoS One. 2020;15:e0235824. doi:10.1371/journal.pone.0235824
37. Wang Q, Guo YZ, Zhang YT, et al. The effects and mechanism of atorvastatin on pulmonary hypertension due to left heart disease. PLoS One. 2016;11:e0157171. doi:10.1371/journal.pone.0157171
38. Hunt JM, Bethea B, Liu X, et al. Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. Am J Physiol Lung Cell Mol Physiol. 2013;305:L725-736. doi:10.1152/ajplung.00186.2013
39. Lambert M, Mendes-Ferreira P, Ghigna MR, et al. Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovasc Res. 2021;117:2474-2488. doi:10.1093/cvr/cvab016
40. Zhang YT, Xue JJ, Wang Q, et al. Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. Life Sci. 2019;219:82-89. doi:10.1016/j.lfs.2018.12.056
41. Chen IC, Tan MS, Wu BN, et al. Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase. Pediatr Pulmonol. 2017;52:443-457. doi:10.1002/ppul.23610
42. Dai ZK, Tan MS, Chai CY, et al. Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatr Pulmonol. 2004;37:249-256. doi:10.1002/ppul.10413
43. Gygógyosi M, Pavo N, Lukovic D, et al. Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. J Transl Med. 2017;15:202. doi:10.1186/s12967-017-1299-0
44. Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA. 1991;88:8277-8281. doi:10.1073/pnas.88.18.8277
45. deAlmeida AC, van Oort RJ, Wehrens XH. Transverse aortic constriction in mice. J Vis Exp. 2010;(38):1729. doi:10.3791/1729
46. Chen JI, Ma WM, Yuan JL, Cui LQ, PM2.5 exposure aggravates left heart failure induced pulmonary hypertension. Acta Cardiol. 2019;74:238-244. doi:10.1007/s10518538.2014.1848568
47. Chen Y, Guo H, Xu D, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension. 2012;59:1170-1178. doi:10.1161/HYPERTENSIONAHA.111.186072
48. Silove ED, Tavernor WD, Berry CL. Reactive pulmonary arterial hypertension after pulmonary venous constriction in the calf. Cardiovasc Res. 1972;6:36-44. doi:10.1093/cvr/6.1.36
49. LaBourene JI, Coles JG, Johnson DJ, et al. Alterations in elastin and collagen related to the mechanism of progressive pulmonary venous obstruction in a piglet model. A hemodynamic, ultrastructural, and biochemical study. Circ Res. 1990;66:438-456. doi:10.1161/01.res.66.6.438
50. Pereda D, García-Alvarez A, Sánchez-Quintana D, et al. Swine model of chronic postcapillary pulmonary hypertension with right ventricular remodeling: long-term characterization by cardiac catheterization, magnetic resonance, and pathology. J Cardiovasc Transl Res. 2014;7:494-506. doi:10.1007/s12265-014-9564-6
51. Aguero J, Ishikawa K, Hadli R, et al. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol Heart Circ Physiol. 2014;307:H1204-H1215. doi:10.1152/ajpheart.00246.2014
52. Fujimoto Y, Urashima T, Kawachi F, et al. Pulmonary hypertension due to left heart disease causes intrapulmonary venous arteriolarization in rats. J Thorac Cardiovasc Surg. 2017;154:1742-1753.e8. doi:10.1016/j.jtcvs.2017.06.053
53. Xiong PY, Baba S, Nishioka N, et al. Left atrial stenosis induced pulmonary venous arteriolarization and group 2 pulmonary hypertension in rat. J Vis Exp. 2018;(141):e58787. doi:10.3791/58787
54. Currie BJ, Johns C, Chin M, et al. CT derived left atrial size identifies left heart disease in suspected pulmonary hypertension: derivation and validation of predictive thresholds. Int J Cardiol. 2018;260:172-177. doi:10.1016/j.ijcard.2018.02.114
55. Aviram G, Rozenbaum Z, Ziv-Baran T, et al. Identification of pulmonary hypertension caused by left-sided heart disease (World Health Organization Group 2) based on cardiac chamber volumes derived from chest CT imaging. Chest. 2017;152:792-799. doi:10.1016/j.chest.2017.04.184
56. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarction. Circulation. 1979;44:503-512. doi:10.1161/01.res.44.4.503
57. Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation. 1998;98:2323-2330. doi:10.1161/01.cir.98.21.2323
58. Nguyen QT, Colombo F, Rouleau JL, Dupuis J, Calderone A. LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol. 2000;130:1525-1530. doi:10.1038/sj.bjp.0703466
59. Jiang BH, Tardif JC, Shi Y, Dupuis J. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. *Eur Respir J*. 2011;37:578-586. doi:10.1183/09031936.00053710

60. Nguyen QT, Nasibia MJ, Sirois MG, et al. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure. *Cardiovasc Res*. 2020;116:171-182. doi:10.1093/cvr/cvz034

61. Reichert K, Colantuono B, McCormack I, et al. Murine left anterior descending (LAD) coronary artery ligation: an improved and simplified model for myocardial infarction. *J Vis Exp*. 2017;(122):55535. doi:10.3791/55535

62. Ravi Y, Selvendiran K, Naidu SK, et al. Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced down-regulation of PTEN in the lung. *Hypertension*. 2013;61:593-601. doi:10.1161/HYPERTENSIONAHA.111.00514

63. Dayeh NR, Tardif JC, Shi Y, et al. Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice. *Sci Rep*. 2018;8:1363. doi:10.1038/s41598-018-19625-2

64. Houweling B, Merkus D, Sorop O, Boomsma F, Duncker DJ. Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction. *Am J Physiol. 2006;574:615-626. doi:10.1152/jphysiol.007060.2006.

65. Meng Q, Lai YC, Kelly NJ, et al. Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction. *Am J Respir Cell Mol Biol*. 2017;56:497-505. doi:10.1165/rcmb.2016-0177OC

66. Kelly NJ, Radder JE, Baust JJ, et al. Mouse genome-wide association study of preclinical group II pulmonary hypertension identifies epidermal growth factor receptor. *Am J Respir Cell Mol Biol*. 2017;56:488-496. doi:10.1165/rcmb.2016-0176OC

67. Krafsur GM, Neary JM, Garry F, et al. Cardiopulmonary remodelling in fattened beef cattle: a naturally occurring large animal model of obesity-associated pulmonary hypertension with left heart disease. *Pulm Circ*. 2019;9:2045894018796804. doi:10.1177/2045894018796804

68. Ranchoux B, Nadeau V, Bourgeois A, et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. *Am J Respir Cell Mol Biol*. 2017;56:488-496. doi:10.1165/rcmb.2016-0176OC

69. Mulkareddy V, Simon MA. Metformin in pulmonary hypertension in left heart disease. *Front Med*. 2020;7:425. doi:10.3389/fmed.2020.00425

70. Lai YC, Tabima DM, Dube JJ, et al. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. *Circulation*. 2019;125:449-466. doi:10.1161/CIRCRESAHA.118.314555

71. Mulkareddy V, Simon MA. Metformin in pulmonary hypertension in left heart disease. *Front Med*. 2020;7:425. doi:10.3389/fmed.2020.00425

72. Zhao JH, He YY, Guo SS, et al. Circulating plasma metabolomic profiles differentiate rodent models of pulmonary hypertension and idiopathic pulmonary arterial hypertension patients. *Am J Hypertens*. 2019;32:1109-1117. doi:10.1093/ajh/hpz121

73. Suzuki R, Yuchi Y, Kanno H, et al. Pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension probability. *Front Vet Sci*. 2021;8:771726. doi:10.3389/fvets.2021.771726

74. Zhao JH, He YY, Guo SS, et al. Circulating plasma metabolomic profiles differentiate rodent models of pulmonary hypertension and idiopathic pulmonary arterial hypertension patients. *Am J Hypertens*. 2019;32:1109-1117. doi:10.1093/ajh/hpz121

75. Li M, Riddle S, Zhang H, et al. Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-1. *Circulation*. 2016;134:1105-1121. doi:10.1161/CIRCULATIONAHA.116.023171

76. Graham BB, Kumar R, Mickael C, et al. Vascular adaptation of the right ventricle in experimental pulmonary hypertension. *Am J Respir Cell Mol Biol*. 2018;59:479-489. doi:10.1165/rcmb.2018-0095OC

77. Izquierdo-Garcia JL, Arias T, Rojas Y, et al. Metabolic reprogramming in the heart and lung in a murine model of pulmonary arterial hypertension. *Front Cardiovasc Med*. 2018;5:110. doi:10.3389/fcvm.2018.00110

78. He YY, Xie XM, Zhang HD, et al. Identification of hypoxia induced metabolism associated genes in pulmonary hypertension. *Front Pharmacol*. 2021;12:753727. doi:10.3389/fphar.2021.753727

79. Ranchoux B, Antigny F, Rucker-Martin C, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. *Circulation*. 2015;131:1006-1018. doi:10.1161/CIRCULATIONAHA.114.008750

80. Hautefort A, Mendes-Ferreira P, Sabourin J, et al. Bmp2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension. *Circulation*. 2019;139:932-948. doi:10.1161/CIRCULATIONAHA.118.033744

81. Yan YI, He YY, Jiang X, et al. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. *Sci Adv*. 2020;6:eaba2470. doi:10.1126/sciadv.eaba2470

82. Zhao L, Chen CN, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. *Circulation*. 2012;126:455-467. doi:10.1161/CIRCULATIONAHA.112.103176

83. Omura J, Abbount K, Shimauchi T, et al. Identification of long noncoding RNA H19 as a New biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension. *Circulation*. 2020;142:1464-1484. doi:10.1161/CIRCULATIONAHA.120.047626

84. Muller M, Grobbee DE, den Tonelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. *J Clin Endocrinol Metab*. 2005;90:2618-2623. doi:10.1210/jc.2004-1158

85. Chen IC, Lin JY, Liu YC, et al. The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. *Int J Med Sci*. 2020;17:2594-2602. doi:10.7150/ijms.48096

86. Yin J, Kukuczka M, Hoffmann J, et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. *Circ Heart Fail*. 2011;4:198-206. doi:10.1161/CIRCHEARTFAILURE.110.957050

87. Wallner M, Eaton DM, Berretta RM, et al. A Feline HPcEF Model with pulmonary hypertension and compromised pulmonary function. *Sci Rep*. 2017;7:16587. doi:10.1038/s41598-017-15851-2

88. Duin RWB, Stam K, Cai Z, et al. Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin. *J Physiol*. 2019;597:1157-1173. doi:10.1113/JP275987

89. Bikou O, Ishikawa K, Fish KM, Zarragoikoetxea I, Hajjar RJ, Aguero J. Modeling pulmonary hypertension: a pig model of postcapillary pulmonary hypertension. *Methods Mol Biol*. 2018;1816:367-383. doi:10.1007/978-1-4939-8597-5_29

90. García-Alvarez A, Pereda D, García-Lunar I, et al. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. *Basic Res Cardiol*. 2016;111:49. doi:10.1007/s00395-016-0567-0

91. Jasmin JF, Mercier I, Hnasko R, et al. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. *Cardiovasc Res*. 2004;63:747-755. doi:10.1016/j.cardiores.2004.05.018

92. Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial...
infarction: complete reversal with irbesartan. *Cardiovasc Res.* 2003;58:621-631. doi:10.1016/s0008-6363(03)00290-6

93. Satoh T, Wang L, Espinosa-Diez C, et al. Metabolic syndrome mediates ROS-miR-193b-NFYA-dependent downregulation of soluble guanylate cyclase and contributes to exercise-induced pulmonary hypertension in heart failure with preserved ejection fraction. *Circulation.* 2021;144:615-637. doi:10.1161/CIRCULATIONAHA.121.053889

**How to cite this article:** Liu S-F, Yan Y. Animal models of pulmonary hypertension due to left heart disease. *Anim Models Exp Med.* 2022;5:197-206. doi:10.1002/ame2.12214